A Phase II, Open-label, Escalating Dose-ranging Study to Evaluate the Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults at least 65 Years of Age.

Trial Profile

A Phase II, Open-label, Escalating Dose-ranging Study to Evaluate the Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults at least 65 Years of Age.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2014

At a glance

  • Drugs VAX 125 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 06 Jun 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Preliminary results presented at the National Foundation for Infectious Diseases' Thirteenth Annual Conference on Vaccine Research.
    • 06 Feb 2010 Additional lead investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top